Mucinex Exploratory Cold Study

Double Blind, Randomized, Placebo Controlled Study of Mucinex® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days

This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.

Inclusion Criteria:

• common cold symptoms
• meet symptom severity
• females of child-bearing potential must have negative pregnancy test and use effective birth control

Exclusion Criteria:

• chronic respiratory conditions
• significant heart, kidney, liver, or lung disease, uncontrolled hypertension or diabetes, cystic fibrosis, thyroid disorder
• pregnant or lactating
• known malignancy
• participation in any other clinical trial within 30 days of baseline
• related to another enrolled patient or persons involved directly or indirectly with the conduct of this study